BRPI0519345A2 - composiÇço para tratamento do hcv - Google Patents

composiÇço para tratamento do hcv

Info

Publication number
BRPI0519345A2
BRPI0519345A2 BRPI0519345-1A BRPI0519345A BRPI0519345A2 BR PI0519345 A2 BRPI0519345 A2 BR PI0519345A2 BR PI0519345 A BRPI0519345 A BR PI0519345A BR PI0519345 A2 BRPI0519345 A2 BR PI0519345A2
Authority
BR
Brazil
Prior art keywords
treatment composition
hcv treatment
agent
hcv
compound
Prior art date
Application number
BRPI0519345-1A
Other languages
English (en)
Inventor
Kai Lin
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0519345A2 publication Critical patent/BRPI0519345A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇÕES PARA TRATAMENTO DO HCV. A presente invenção refere-se a uma combinação farmacêutica compreendendo a) um primeiro agente o qual é uma ciclosporina de ligação de ciclofilina não imunossupressiva, por exemplo, um composto de fórmula I e b) um co-agente.
BRPI0519345-1A 2004-12-23 2005-12-20 composiÇço para tratamento do hcv BRPI0519345A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867504P 2004-12-23 2004-12-23
PCT/US2005/046059 WO2006071619A1 (en) 2004-12-23 2005-12-20 Compositions for hcv treatment

Publications (1)

Publication Number Publication Date
BRPI0519345A2 true BRPI0519345A2 (pt) 2009-01-20

Family

ID=36155247

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519345-1A BRPI0519345A2 (pt) 2004-12-23 2005-12-20 composiÇço para tratamento do hcv

Country Status (16)

Country Link
US (1) US7897565B2 (pt)
EP (1) EP1830871A1 (pt)
JP (1) JP2008525459A (pt)
KR (1) KR20070087624A (pt)
CN (1) CN101076350A (pt)
AU (1) AU2005322242B2 (pt)
BR (1) BRPI0519345A2 (pt)
CA (1) CA2587793A1 (pt)
IL (1) IL183659A0 (pt)
MA (1) MA29098B1 (pt)
MX (1) MX2007007779A (pt)
NO (1) NO20073764L (pt)
NZ (1) NZ555143A (pt)
RU (1) RU2007128099A (pt)
WO (1) WO2006071619A1 (pt)
ZA (1) ZA200703908B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
WO2006071618A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
CA2587793A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
AR054778A1 (es) * 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
EP1909564A4 (en) * 2005-07-18 2010-06-30 Novartis Ag SMALL ANIMAL MODEL FOR HCV REPLICATION
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
US10752611B2 (en) 2009-02-27 2020-08-25 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
BR112012014729A2 (pt) * 2009-12-18 2016-03-29 Boehringer Ingelheim Int terapia combinada contra hcv
KR20140035305A (ko) 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
BR112013013166A2 (pt) 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN105749246A (zh) 2011-03-31 2016-07-13 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
PL2694087T3 (pl) 2011-04-01 2015-06-30 Novartis Ag Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
SG10201602184TA (en) 2011-04-13 2016-04-28 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
KR20140070565A (ko) 2011-09-27 2014-06-10 노파르티스 아게 C형 간염 바이러스 감염의 치료를 위한 알리스포리비르
SG11201406441RA (en) 2012-05-07 2014-11-27 Novartis Ag Pharmacokinetic modulation with alisporivir
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
TW201536789A (zh) 2013-07-29 2015-10-01 Enanta Pharm Inc Ｃ型肝炎病毒抑制劑
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
ATE148469T1 (de) 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AR031010A1 (es) * 2000-10-19 2003-09-03 Fujisawa Pharmaceutical Co Una composicion farmaceutica, util para inhibir el dano celular
AR036081A1 (es) * 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
CA2503693A1 (en) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
RU2005123395A (ru) * 2002-12-23 2006-01-27 Айденикс (Кайман) Лимитед (Ky) Способ получения 3-нуклеозидных пролекарств
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
UA88484C2 (ru) 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
CA2587793A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
KR20070087624A (ko) 2007-08-28
IL183659A0 (en) 2007-09-20
CA2587793A1 (en) 2006-07-06
US7897565B2 (en) 2011-03-01
MX2007007779A (es) 2007-08-14
JP2008525459A (ja) 2008-07-17
WO2006071619A1 (en) 2006-07-06
AU2005322242A1 (en) 2006-07-06
ZA200703908B (en) 2009-06-24
AU2005322242B2 (en) 2010-02-11
EP1830871A1 (en) 2007-09-12
NZ555143A (en) 2009-12-24
NO20073764L (no) 2007-09-18
RU2007128099A (ru) 2009-01-27
MA29098B1 (fr) 2007-12-03
US20090104149A1 (en) 2009-04-23
CN101076350A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
NO20073764L (no) Sammensetninger for behandling av HCV
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
BRPI0414062B8 (pt) uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BRPI0411528A (pt) uso de isomalte como prebiótico
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
ECSP088429A (es) Diarilureas para el tratamiento de la hipertensión pulmonar
UY37832A (es) Dihidrooxadiazinonas
DOP2009000094A (es) Inhibidores de la proteasa ns3 del hcv
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
BRPI0607308A2 (pt) compostos, composições farmacêuticas e usos dos referidos compostos
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MX2009009176A (es) Inhibidores de serina-proteasas.
BRPI0612104A8 (pt) composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente
PL1948155T3 (pl) Kompozycje farmaceutyczne zawierające droksidopę
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
TNSN07240A1 (en) Compounds for flaviviridae treatment
CL2020002891A1 (es) Nuevos derivados de quinolina
EA200970132A1 (ru) Аналоги морфолинила и пирролидинила

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.